Our R&D strategy for a thriving product pipeline
As a global biopharmaceutical company with a focus on innovation and specialty care, Ipsen is building a strong and sustainable portfolio of medicines to meet patients’ and their healthcare teams’ needs. We prioritize best-in-class and first-in-class treatments in oncology, rare disease, and neuroscience – areas in which we have proven experience, global capabilities, and a strong network of partners.
Key facts
Investing heavily in R&D
€687m invested in R&D in 2024, sustaining a high-value pipeline.
Precision focus in 3 therapeutic areas
Since 2020, Ipsen has brought in more than 30 programs across our three focus areas of Oncology, Rare disease, and Neuroscience at every stage of development.
Investing in a strong future
Ipsen has been around for around 100 years and plan to be around for another 100. We have significant firepower to invest in the development of next-generation medicines through the pipeline.
Our expert teams and facilities
700 R&D colleagues span three global sites in France, the UK and the US, supported by dedicated research and manufacturing facilities worldwide – including state-of-the-art capabilities in Wrexham, UK to develop and produce neurotoxins.
End-to-end expertise
Ipsen execute across all stages and geographies, leveraging our global footprint, end-to-end capabilities, and scalable operations that flex to portfolio needs.
Building a high-value, sustainable pipeline
Filters
Disease Areas
Phase
Phase – l
Phase – ll
Phase – lll
Registration
IPN01195
Solid tumors
IPN01194
Solid tumors
Tazverik + R2
2L FL
Tovorafenib
1L pLGG
Iqirvo
PSC
Fidrisertib
FOP
Iqirvo
PBC
Bylvay
BA
IPN10200
Cervical dystonia (Tx)
IPN10200
GL, FHL, LCL (Ax)
IPN10200
Migraine (Tx)
IPN10200
AUL (Tx)
Dysport
Chronic migraine
Dysport
Episodic migraine
Information shown as of September 2025
| R2 | lenalidomide + rituximab |
| 2L | second line |
| FL | follicular lymphoma |
| 1L | first line |
| pLGG | pediatric low-grade gliomas |
| ERKi | ERK inhibitor of the MAPK pathway |
| RAFi | RAF inhibitor of the MAPK pathway |
| BA | Biliary Atresia |
| PBC | primary biliary cholangitis |
| PSC | primary sclerosing cholangitis |
| FOP | fibrodysplasia ossificans progressiva |
| GL | glabellar lines |
| FHL | forehead lines |
| LHL | lateral canthal lines |
| AUL | adult upper limb spasticity |
| Ax | aesthetics |
| Tx | therapeutics |
Our Partnerships
Ipsen are building a high-impact pipeline driven by external innovation. We seek to build purpose-led partnerships that boost our capacity to improve or extend the lives of people living with cancer, rare diseases and neurological conditions.
Learn moreClinical Trials
Ipsen are building a high-impact pipeline driven by external innovation. We seek to build purpose-led partnerships that boost our capacity to improve or extend the lives of people living with cancer, rare diseases and neurological conditions.